within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04A_DrugsForTreatmentOfTuberculosis.J04AB06_Enviomycin;

model Enviomycin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 1.3333333333333332e-06,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.00022,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Enviomycin</td></tr><tr><td>ATC code:</td><td>J04AB06</td></tr><td>route:</td><td>intramuscular</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.22</td><td>L</td></tr>
    <tr><td>clearance:</td><td>80</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Enviomycin is an aminoglycoside antibiotic formerly used primarily for the treatment of tuberculosis, particularly multidrug-resistant Mycobacterium tuberculosis. It is not widely approved or used today, having largely been replaced by other agents due to its side effect profile and availability of alternatives.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical adult patient; no direct human clinical literature source was found. Values are based on typical pharmacokinetics of aminoglycosides and limited available animal studies.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J04AB06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Enviomycin;
